COVID-19 (Coronavirus) Daily Updates and ResourcesCOVID Resources
Hematology, Oncology and Palliative Care
The Division of Hematology, Oncology and Palliative Care is a specialized group of physicians, healthcare providers, researchers and professors that provides for the unique medical and supportive care needs of patients in the greater Richmond area and throughout the state of Virginia. As part of VCU Massey Cancer Center, a National Cancer Institute-designated Cancer Center, division members are also [View Image]
involved in developing the latest cancer treatments by conducting research and translating their discoveries into cutting-edge patient care. And as part of the VCU School of Medicine, division faculty, each member of our diverse faculty contributes his or her expertise and experience to our patient care, research and teaching missions. A collaborative environment among division faculty, and with other specialists from multiple disciplines, provides a comprehensive approach to patient care and physician training.
VCU Massey Cancer Center coordinates the following multidisciplinary programs:
Inpatient clinical services offered at the VCU Medical Center on the MCV Campus in downtown Richmond include a 28-bed acute care oncology floor in the Critical Care Hospital, a 21-bed bone marrow transplantation unit and the 11-bed Thomas Palliative Care Unit. Outpatient services are provided at the flagship Dalton Oncology Clinic located in North Hospital on the MCV campus of the VCU Medical Center, and at our conveniently located suburban practice at Stony Point. Several faculty members also work in conjunction with the Hunter Holmes McGuire VA Medical Center in south Richmond. In addition, the division directs the hematology-oncology services at Community Memorial Healthcenter in South Hill, VA, which are offered five days per week. Division doctors also staff the hematology-oncology clinic at Riverside Tappahannock Hospital as part of VCU Massey Cancer Center’s Rural Cancer Outreach Program
Teaching and training are core components of the practice. The division provides comprehensive clinical training in hematology, medical oncology, and palliative care. Research training in preparation for academic careers is integral to both programs. The division has a Hematology/Oncology Fellowship Program and a Palliative Care Fellowship Program. Seasoned faculty members are often paired with young physicians training in the hematology, oncology or palliative care specialties. These learning relationships not only provide critical training for junior physicians, but also help ensure the division remains current with the latest advancements in the field and help reinforce key concepts. The didactics curriculum allows faculty and trainees to review all areas of the specialty, and weekly conferences including hematology-oncology Grand Rounds and multiple tumor-specific multidisciplinary conferences provide an opportunity to engage with experts and to learn about clinical research in the field. Practice-based learning and improvement conferences take place weekly, and regularly scheduled journal clubs provide a forum for nuanced discussion of the most recently published data.
In addition, the Thomas Palliative Care Program offers clinical training for practicing health care professionals through the Center to Advance Palliative Care Leadership Program and the Virginia Initiative for Palliative Care. Our palliative care program is the first and only palliative care program in Virginia and one of only two dozen in the nation to receive accreditation and certification by the Joint Commission.
Our faculty is organized by their expertise in the following specialties:
Personalized, Coordinated, and Multidisciplinary Care:
Hematology-oncology and palliative care specialists collaborate with clinicians from many different disciplines in the area’s largest and most comprehensive multidisciplinary teams. VCU Massey Cancer Center is the leader in Central Virginia in developing and extending this highly coordinated care.
Cohesive teams of medical and radiation oncologists, surgeons, radiologists, gastroenterologists, pulmonologists, pathologists, genetic counselors, clinical research nurses, physical therapists, nutritionists, and social workers, among others, come together regularly to customize each individual patient’s course of treatment.
VCU Massey Cancer Center does this for more cancers and more patients than any other center in Central Virginia. This level of teamwork and communication is unparalleled and provides the highest-quality, personalized care – all culminating in better outcomes for patients.
The Advantages of Our Multidisciplinary Approach:
Recognized with the Complex & Rare Cancer Center designation from Blue Cross & Blue Shield, VCU Massey Cancer Center excels at treating not just the most common cancers, such as breast, colorectal, prostate and lung, but also at treating the most complex and rare cancers, such as acute leukemia, primary brain cancer, melanoma, sarcoma, esophageal cancer, gastric cancer, head and neck cancers, liver cancer and pancreatic cancer. This designation is based upon the Massey specialists’ extensive depth of training, variety of specialists who work together to plan and carry out complex treatments and a high volume of rare and complex cancers.
The Division of Hematology, Oncology and Palliative Care is dedicated to the performance of cutting edge research in the Hematology, Oncology and Palliative Care field. The division physicians and investigators have received significant NIH funding, and faculty members receive awards from public and private entities in support of basic and clinical research.
Project Number: 5R01CA188571-04
Cell proliferation is controlled by the mechanisms that promote quiescence and senescence; deregulation of these processes leads to cancer. DYRK1A protein kinase is required for quiescence and senescence by promoting the functions of the retinoblastoma family of tumor suppressors. The mechanisms of functionand regulation of DYRK1A are poorly understood, therefore this grant proposes to elucidate the DYRK1A signaling pathway, which controls cell proliferation and could play a role in the pathogenesis of cancer.
Project Number: 1R01DK115563-01A1
This project is aimed at alleviating the major public health problem posed by sickle cell anemia and β-Thalassemia through facilitating development of new safe and effective treatment. The fundamental epigenetic mechanisms under study controlled by the MBD2-NURD transcriptional protein complex also bear on hematologic malignancies and other cancers.
Project Number: 5R01CA205607-04
Despite recent advances, multiple myeloma remains an incurable disease, and consequently, new and more effective treatment approaches are urgently needed. The purpose of this project is to develop a novel therapeutic strategy involving two new classes of agents (i.e., Smac-mimetics and histone deacetylase inhibitors) that target important genetically abnormal pathways in multiple myeloma, with the ultimate goal of developing a rational basis for a new therapy for refractory/relapsed multiple myeloma, a disease for which satisfactory treatment options are currently lacking.
Delirium or altered mental state is a critical yet poorly understood and undertreated problem in patients with advanced cancer admitted for palliative care. This project will test the effect of novel combination therapies that include neuroleptics and benzodiazepine rotation on a score for delirium developed at VCU, the Richmond Agitation Sedation Score (RASS). Outcomes will also include caregiver comfort, delirium related stress in caregivers and nurses and symptom expression, along with molecular correlates that will be tested such as IL-6 and IL-8 for future predictive biomarkers.
Ovarian cancer has lagged other cancers in the development of targeted therapy due to the lack of gene mutations that are required for efficacy of this newest class of anti-cancer agents. As such, chemotherapy remains the mainstay of ovarian cancer treatment. This work provides a new path forward for ovarian cancer, by defining a novel transcription factor target. CtBP, as key to progression of ovarian cancer. The work will test a novel chemical inhibitor of CtBP that has shown efficacy in colon and breast cancer, to determine if it will slow progression or eradicate ovarian cancer in a variety of mouse models of human ovarian cancer.
Division of Hematology, Oncology and Palliative Care
1201 East Marshall Street
11th floor, Suite 11-206
Richmond, VA 23298-0230
Phone: (804) 828-9723
Fax: (804) 828-8079
Phone: (804) 828-7999
Fax: (804) 828-5941
New Patient Appointments: (804) 828-5116
Steven R. Grossman, MD, PhD
Deputy Director, VCU Massey Cancer Center
Dianne Nunnally Hoppes Endowed Chair in Cancer Research, VCU Massey Cancer Center
Phone: (804) 828-5662
Khalid Matin, MD, FACP
Medical Vice Chair, Clinical Affairs & Director of Community Oncology and Clinical Research Affiliations, Massey Cancer Center
Phone: (804) 628-2945
John McCarty, MD
Phone: Director, Bone Marrow Transplant Program
Egidio Del Fabbro, MD
Phone: Director, Palliative Care Program
Shejal Patel, DO
Medical Director, In-Patient Oncology
Phone: (804) 828-7999
Andrew Poklepovic, MD
Medical Director, Ambulatory Oncology
Phone: (804) 828-7999
Sherman Baker, MD
Medical Director, Cerner Oncology
Phone: (804) 828-9723
Nemer Junior El Mouallem, MD
Medical Director, CMH Cancer & Specialty Care Center in South Hill, VA
Phone: (434) 447-0876
Mary Helen Hackney, MD
Director, Quality Improvement
Phone: (804) 628-1933
Phone: (804) 828-9643
Phone: (804) 628-0617
Phone: (804) 628-4927
Phone: (804) 828-5662
Phone: (804) 828-9692